Approval · Notice of Compliance 23701 · 2020
ENSPRYNG: Notice of Compliance 23701
Issued June 1, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23701
- Date
- June 1, 2020
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENSPRYNG | 02499681 | Marketed |
Medicinal ingredients
- SATRALIZUMAB 120 MG per ML